The Phase I study, conducted in France, assessed the safety, tolerability, pharmacokinetics and pharmacodynamics of SCYX-7158 after single oral ascending doses in 128 healthy human volunteers of sub-Saharan
When fully operational in 2017, the factory will make more than 8 billion tablets and 1 billion capsules in the areas of gastroenterology and anti-inflammatory medicines for the
Exploration into cell metabolism is rapidly accelerating as the links between mitochondrial function and disease are increasingly revealed. Seahorse Bioscience’s leading technology enables researchers to better understand cell
As part of this arrangement, Recipharm will also acquire Alcon’s manufacturing facility located in Kaysersberg, France. The 260 people currently employed at the Kaysersberg site would transfer and
The data being presented today at the World Conference on Lung Cancer (WCLC) 2015 were from the AURA Phase I trial first-line cohort and two AURA Phase II
EXPAREL was approved in 2011 for administration into the surgical site to produce postsurgical analgesia. The complaint outlines the Company’s belief that the FDA has violated the Administrative
The proprietary technology was originally developed by a team headed by Prof. Ehud Gazit of the George S. Wise Faculty of Life Sciences at Tel Aviv University. The
After successfully completing preliminary studies of ISCO’s human parthenogenetic neural stem cells (hpNSCs) Rohto acknowledged that ISCO’s proprietary cells demonstrate consistent high quality and are suitable for further
The previously disclosed September 8, 2015 PDUFA date has been extended by the standard extension period of three months. In response to a recent request from the FDA,
The procedure, in which all five of the patient’s brain metastases were treated, took less than 20 minutes, including setup time using the Brainlab technology. Using the traditional
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.